54 Smith & Nephew Annual Report 2012 Principal risks and risk management As an integral part of planning and review, Group and business Committee may re-categorise risks or require further information on area management seek to identify the significant risks involved the risk management action plans.
The Risk Committee reports to the in the business, and to review the risk management action plans Board on an annual basis detailing all principal risks.
In addition, the for those risks.
The Group Risk Committee, which is comprised of Board considers risk as part of the development of strategy.
Internal the CEO and senior executives, meets twice a year to review the audit reviews and reports on the effectiveness of the operation of the risks identified by the businesses and corporate functions and any risk management process.
risk management actions being taken.
As appropriate, the Risk Risk Context Specific risks we face The medical devices industry has a rapid rate of new product Competitors may introduce a disruptive technology, Disruptive or obtain patents or other intellectual property rights, introduction.
The Group must be adept at monitoring the landscape for technologies that affect the Groups competitive position technological advances, make good investment acquisition choices, have an efficient and valuable product development pipeline and secure Claims by third parties regarding infringement of their protection for its intellectual property.
intellectual property rights Lack of innovation due to low R&D investment, R&D skills gap or poor product development execution for established and emerging markets Failure to successfully commercialise a pipeline product, or failure to receive regulatory approval In most markets throughout the world, expenditure on medical devices Reduced reimbursement levels and increasing Government pricing pressures is controlled to a large extent by governments, many of which are facing action, increasingly intense budgetary constraints.
The Group is therefore largely Reduced demand for elective surgery dependent on governments providing increased funds commensurate pricing and Increased focus on health economics with the increased demand arising from demographic trends.
reimbursement Government policies favouring lower priced products Reimbursement rates may be set in response to perceived economic pressure value of the devices, based on clinical and other data relating to cost, Political upheavals prevent selling of products, patient outcomes and comparative effectiveness.
Political upheaval in receiving remittances of profit from a member of the the countries where the Group operates or surrounding regions could Group or future investments in that country adversely affect Group operations or turnover.
The Group is exposed to fluctuations in exchange rates.
If the manufacturing country currencies Group operations are affected by transactional exchange rate strengthen against the selling currencies, the trading movements.
The Groups manufacturing cost base is situated in the margin may be affected US, UK, China and Switzerland and finished products are exported Economic downturn impacts demand and collections worldwide.
Unexpected events could disrupt the business by affecting either a key Catastrophe could render one of the Groups Supply, production facilities out of action facility or system or a large number of employees.
The business is also system and site reliant on certain key suppliers of raw materials, components, finished A significant event could impact key leadership or a products and packaging materials.
large number of employees disruption Issues with a single source supplier of a key component and failure to secure critical supply A severe IT fault could disable critical systems National regulatory authorities enforce a complex series of laws and Non-compliance with product regulations and Product safety, standards could result in fines, penalties, and regulations that govern the design, development, approval, manufacture, regulation, and prosecutions labelling, marketing and sale of healthcare products.
They also review data supporting the safety and efficacy of such products and may also litigation Product defect could result in lost sales and inventory inspect for compliance with appropriate standards, including those write-offs relating to Quality Management Systems QMS or Good Manufacturing Third party liability claims Practice GMP regulations.
Damage to reputation Business practices in the healthcare industry are subject to increasing Violation of healthcare, data privacy or anti-corruption Compliance laws could result in fines, loss of reimbursement and scrutiny by government authorities.
The trend in many countries is with laws impact reputation towards increased enforcement activity.
The Group is also subject to increased regulation of personal information.
Acquisitions and expansion and regulations Serious breaches could potentially prevent the Group into Emerging markets could also pose additional compliance risks.
from doing business in a certain market Failure to conduct adequate due diligence or to integrate appropriate internal controls into acquired businesses could result in fines and impact return oninvestment 015914 Smith&Nephew AR12 p54-p55 Working Copy.
indd 54 26 02 2013 09:35 marketplace and sustainability financial review corporate accounts and overview strategy and performance business segment review review and principal risks governance other information section 5 financial review and principal risks 55 There are known and unknown risks and uncertainties relating to historical levels, and how these risks relate to the Groups strategic Smith & Nephews business.
The table below provides an overview priorities.
In addition, other factors not listed here that Smith & Nephew of what the Board considers the most significant risks that could cannot presently identify or does not believe to be equally significant, cause the Groups business, financial position and results of could also materially adversely affect Smith & Nephews business, operations to differ materially and adversely from expected and financial position or results of operations.
Possible impacts Risk Management actions Link to strategic priority Loss of market share, Increasing productivity, prioritisation and allocation of R&D funds Innovate for value profit and long-term Increasing R&D investment in order to enhance clinical capability, invest Simplify and improve our operating model growth in biomaterials Supplement the organic growth through acquisitions Strengthen intellectual property rights and support an Emerging Market portfolio Business development to augment the portfolio Increasing speed to market of new products Loss of revenue, profit Develop innovative economic product and service solutions for both Simplify and improve our operating model Established and Emerging markets Established markets and cash flows Incorporate health economic component into design and development Innovate for value of new products Enhanced expertise supporting reimbursement strategy and guidance Optimise cost to serve to protect margins and liberate funds for investment Streamline COGS, SKUs, and inventory management The Group transacts forward foreign currency commitments when firm purchase orders are placed to reduce exposure to currency fluctuations Loss of revenue, profit Ensure crisis response business continuity plans at all major facilities Simplify and improve our operating model and for key products and cash flows Established markets Audit programme for critical suppliers and second sources or increased inventories for critical components Implement enhanced travel security and protection programme IT disaster and data recovery plans are in place and support overall business continuity plans Loss of profit and Enhanced leadership and resources Simplify and improve our operating model reduction in share price Standardise the Groups quality management and practice Innovate for value Negative impact on Maintain auditing programmes to assure compliance brand reputation Group-wide practices to drive design, and production line performance and dependability Post launch review of product safety and complaint data Loss of profit and Strong compliance expertise and infrastructure Simplify and improve our operating model reduction Code of Conduct Global Policies and Procedures GPPs providing Emerging markets in share price controls for significant compliance risks Established markets Negative impact on Training and e-resources to guide employees and third parties with brand reputation compliance responsibilities Monitoring and auditing programmes to verify implementation Independent reporting channels for employees and third parties to report concerns with confidentiality D ue diligence reviews and integration plans required for acquisitions 015914 Smith&Nephew AR12 p54-p55 Working Copy.
indd 55 26 02 2013 09:35 56 56 S Sm miit th & N h & Ne ep ph he ew A w An nn nu ua al R l Re ep po or rt 2 t 20 01 12 2 Corporate Governance 6 Ethics and compliance are at the heart of everything we do, and underline our commitment to strong Governance.
We believe effective Governance requires both leadership and collaboration.
Governance introduction 57 Our Board of Directors 58 Our Executive Officers 60 Corporate Governance Statement 62 Directors Remuneration Report 74 015914 Smith&Nephew AR12 p56-p73 Working Copy.
